These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 23349488)
1. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of α-synuclein levels in β-cells. Steneberg P; Bernardo L; Edfalk S; Lundberg L; Backlund F; Ostenson CG; Edlund H Diabetes; 2013 Jun; 62(6):2004-14. PubMed ID: 23349488 [TBL] [Abstract][Full Text] [Related]
3. Pancreatic β-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and β-cell functional immaturity. Fernández-Díaz CM; Merino B; López-Acosta JF; Cidad P; de la Fuente MA; Lobatón CD; Moreno A; Leissring MA; Perdomo G; Cózar-Castellano I Am J Physiol Endocrinol Metab; 2019 Nov; 317(5):E805-E819. PubMed ID: 31479304 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological activation of insulin-degrading enzyme improves insulin secretion and glucose tolerance in diet-induced obese mice. Sanz-González A; Cózar-Castellano I; Broca C; Sabatier J; Acosta GA; Royo M; Hernándo-Muñoz C; Torroba T; Perdomo G; Merino B Diabetes Obes Metab; 2023 Nov; 25(11):3268-3278. PubMed ID: 37493025 [TBL] [Abstract][Full Text] [Related]
5. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. Abdul-Hay SO; Kang D; McBride M; Li L; Zhao J; Leissring MA PLoS One; 2011; 6(6):e20818. PubMed ID: 21695259 [TBL] [Abstract][Full Text] [Related]
6. Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans. Bensellam M; Shi YC; Chan JY; Laybutt DR; Chae H; Abou-Samra M; Pappas EG; Thomas HE; Gilon P; Jonas JC Diabetologia; 2019 Dec; 62(12):2273-2286. PubMed ID: 31624901 [TBL] [Abstract][Full Text] [Related]
7. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421 [TBL] [Abstract][Full Text] [Related]
8. Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging. Corraliza-Gomez M; Bermejo T; Lilue J; Rodriguez-Iglesias N; Valero J; Cozar-Castellano I; Arranz E; Sanchez D; Ganfornina MD J Neuroinflammation; 2023 Oct; 20(1):233. PubMed ID: 37817156 [TBL] [Abstract][Full Text] [Related]
9. Insulin-degrading enzyme is activated by the C-terminus of α-synuclein. Sharma SK; Chorell E; Wittung-Stafshede P Biochem Biophys Res Commun; 2015 Oct; 466(2):192-5. PubMed ID: 26343304 [TBL] [Abstract][Full Text] [Related]
11. α-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Geng X; Lou H; Wang J; Li L; Swanson AL; Sun M; Beers-Stolz D; Watkins S; Perez RG; Drain P Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E276-86. PubMed ID: 20858756 [TBL] [Abstract][Full Text] [Related]
12. Loci of TCF7L2, HHEX and IDE on chromosome 10q and the susceptibility of their genetic polymorphisms to type 2 diabetes. Nordman S; Ostenson CG; Efendic S; Gu HF Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):186-90. PubMed ID: 19053027 [TBL] [Abstract][Full Text] [Related]
13. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD. Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348 [TBL] [Abstract][Full Text] [Related]
14. cAMP/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer's disease. Li H; Yang S; Wu J; Ji L; Zhu L; Cao L; Huang J; Jiang Q; Wei J; Liu M; Mao K; Wei N; Xie W; Yang Z J Cell Biochem; 2018 Feb; 119(2):1616-1626. PubMed ID: 28771808 [TBL] [Abstract][Full Text] [Related]
15. Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits. Borges DO; Patarrão RS; Ribeiro RT; de Oliveira RM; Duarte N; Belew GD; Martins M; Andrade R; Costa J; Correia I; Boavida JM; Duarte R; Gardete-Correia L; Medina JL; Raposo JF; Jones JG; Penha-Gonçalves C; Macedo MP Metabolism; 2021 May; 118():154735. PubMed ID: 33631143 [TBL] [Abstract][Full Text] [Related]